AK 3012

· Dolorgiet GmbH & Co. KG

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AK 3012, covering 2014-05-14 to 2014-05-14. Get the full timeline:

Most recent: Clinical Trial Update: Study Whose Purpose is to Find an Optimal Dose for the Treatment With AK 3012 in Patients With Actinic Keratosis [Phase 2]

See pricing